Stock ATX AMPLIA THERAPEUTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Amplia Therapeutics Limited

Equities

ATX

AU0000023822

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 02:10:24 2024-07-12 am EDT 		5-day change 1st Jan Change
0.062 AUD +3.33% Intraday chart for Amplia Therapeutics Limited +1.64% -22.50%
Jul. 03 Amplia Therapeutics Completes Enrollment for Phase 2A Pancreatic Cancer Trial; Shares Up 3% MT
May. 30 Amplia Therapeutics Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024
Capitalization 1 5.743 3.855 28.07 28.11 16.49 14.94
Enterprise Value (EV) 1 4.502 2.747 26.22 15.6 9.51 13.14
P/E ratio -2.98 x -1.27 x -10.8 x -5.79 x -2.64 x -3.32 x
Yield - - - - - -
Capitalization / Revenue 114 x 113 x 18.3 x 14.2 x 13.9 x 3.35 x
EV / Revenue 89.2 x 80.3 x 17.1 x 7.87 x 7.99 x 2.95 x
EV / EBITDA -2.38 x -1.24 x -11.2 x -4.29 x -1.52 x -2.88 x
EV / FCF -15.7 x -2.18 x -12.5 x -5.07 x -3.18 x -3.66 x
FCF Yield -6.39% -45.9% -8.02% -19.7% -31.4% -27.3%
Price to Book 0.66 x 0.45 x 2.72 x 1.29 x 1.04 x 1.31 x
Nbr of stocks (in thousands) 41,023 66,463 107,973 193,854 194,006 194,006
Reference price 2 0.1400 0.0580 0.2600 0.1450 0.0850 0.0770
Announcement Date 6/27/19 6/25/20 6/29/21 5/29/22 5/30/23 5/30/24
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024
Net sales 1 0.0505 0.0342 1.534 1.983 1.189 4.453
EBITDA 1 -1.889 -2.222 -2.339 -3.64 -6.276 -4.56
EBIT 1 -1.89 -2.223 -2.34 -3.644 -6.286 -4.57
Operating Margin -3,744.98% -6,495.43% -152.6% -183.72% -528.45% -102.64%
Earnings before Tax (EBT) 1 -1.87 -2.219 -2.281 -3.644 -6.242 -4.503
Net income 1 -1.87 -2.219 -2.281 -3.644 -6.242 -4.503
Net margin -3,704.79% -6,484.57% -148.75% -183.74% -524.8% -101.14%
EPS 2 -0.0470 -0.0458 -0.0241 -0.0250 -0.0322 -0.0232
Free Cash Flow 1 -0.2876 -1.261 -2.103 -3.074 -2.986 -3.59
FCF margin -569.76% -3,683.47% -137.11% -155% -251.02% -80.63%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 6/27/19 6/25/20 6/29/21 5/29/22 5/30/23 5/30/24
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024
Net Debt 1 - - - - - -
Net Cash position 1 1.24 1.11 1.85 12.5 6.98 1.8
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -0.29 -1.26 -2.1 -3.07 -2.99 -3.59
ROE (net income / shareholders' equity) -33.9% -25.7% -24.1% -22.6% -33.1% -33%
ROA (Net income/ Total Assets) -20% -15.2% -14.6% -12.9% -18.2% -17%
Assets 1 9.366 14.62 15.59 28.29 34.3 26.43
Book Value Per Share 2 0.2100 0.1300 0.1000 0.1100 0.0800 0.0600
Cash Flow per Share 2 0.0300 0.0200 0.0200 0.0800 0.0500 0.0200
Capex 1 0 - 0.01 0.01 0.02 0
Capex / Sales 6.32% - 0.35% 0.73% 1.48% 0.05%
Announcement Date 6/27/19 6/25/20 6/29/21 5/29/22 5/30/23 5/30/24
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
AMPLIA THERAPEUTICS LIMITED Stock Amplia Therapeutics Limited
-22.50% 11.44M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+20.12% 126B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+25.25% 119B
ARGENX SE Stock argenx SE
+25.56% 27.95B
BIONTECH SE Stock BioNTech SE
-19.51% 20.5B
GENMAB A/S Stock Genmab A/S
-14.36% 17.12B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.63% 16.1B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-46.67% 14.97B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+11.89% 14.84B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+57.74% 14.38B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ATX Stock
  4. Financials Amplia Therapeutics Limited